Cancer Vaccines
Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
Published in Proteomics Weekly, June 11th, 2007
Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that interim clinical trial results demonstrated that a DNA-based immunotherapy delivered by Inovio's electroporation technology was safe and tolerable, facilitated gene expression, and resulted in significant objective tumor responses in treating melanoma. Inovio's electroporation-mediated DNA delivery system is designed to enhance the potency of DNA-based immunotherapies against cancers and infectious diseases.
This investigator-sponsored Phase I clinical trial,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
Source: Proteomics Weekly (2007-06-11)
More Articles from Proteomics Weekly
- Breast Cancer
Researchers Home In On Possible New Breast Cancer Gene - Biochemistry
Alfacell and University of Bath Collaborators Identify Structure of Amphinase - Biotechnology
Eurofins Medigenomix / MWG Biotech sequence Wacker Chemie AG's bacterial protein production strain - Cancer
Analysis Reveals Extent of DNA Repair Army - DNA Research
Applied DNA Sciences Enters Printing Ink Markets, Signs Agreement with Printcolor Screen Ltd., Switzerland - DNA Research
IdentiGEN Opens North American Laboratory for World's First DNA-Based Meat Traceability System - More from this issue of Proteomics Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
